Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Multiple myeloma (MM) is a plasma-cell malignancy derived from an early precursor of the B-cell lineage characterised by bone-marrow infiltration, lytic bone lesions, and the presence of a monoclonal protein in serum and/or urine. Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator in B-cell development and function that i...
Alternative Titles
Full title
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5334380
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5334380
Other Identifiers
ISSN
0004-069X
E-ISSN
1661-4917
DOI
10.1007/s00005-016-0442-6
